Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it
Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to run, the CEO revealed on the conference call.
Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)
Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 guidance raised to $671–681M, while margins compressed due to intentional reinvestment in AI and sales. AI tools, especially Doximity Ask, are rapidly integrating into physician workflows, positioning DOCS for deeper engagement and future monetization opportunities.
Doximity, Inc. (DOCS) Q1 2027 Earnings Call Transcript
Doximity, Inc. (DOCS) Q1 2027 Earnings Call Transcript
Doximity (DOCS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Doximity (DOCS) Q1 Earnings Lag Estimates
Doximity (DOCS) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.36 per share a year ago.
Ahead of Doximity (DOCS) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Doximity (DOCS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Doximity (DOCS) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $20.99, signifying a +2.79% move from its prior day's close.
Doximity (DOCS) Declines More Than Market: Some Information for Investors
Doximity (DOCS) closed at $21.52 in the latest trading session, marking a -3.11% move from the prior day.
Reasons to Retain Doximity Stock in Your Portfolio for Now
DOCS is ramping up AI across physician workflows and enterprise tools, but weak pharma ads and higher AI spending may test near-term growth.
Doximity (DOCS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Doximity (DOCS) stood at $21.77, denoting a -1.09% move from the preceding trading day.
Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories
Doximity issued conservative FY2027 guidance, projecting 4% revenue growth and a 49% adjusted EBITDA margin, triggering a post-earnings stock selloff. I view the selloff as a temporary dislocation and a compelling buying opportunity for value investors given DOCS's resilient core platform usage. Management emphasized record physician engagement and continued dominance of DOCS's core products despite macroeconomic and regulatory headwinds.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Doximity (DOCS) concluded the recent trading session at $19.85, signifying a -4.7% move from its prior day's close.
